Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Autor: Elizabeth Jane Hovey, Sumanta K. Pal, Eric Voog, Thomas Powles, Bernard Escudier, Thierry Gil, Katharine Cuff, Robert J. Motzer, Reinhard Depenbusch, Izzy Cornelio, Louise M. Nott, Christine Chevreau, Sylvie Negrier, Carsten Grüllich, Frede Donskov, Toni K. Choueiri, Anne Champsaur, Lothar Bergmann, Niels Viggo Jensen
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
Pyridines
METEOR
Tyrosine kinase inhibitor
Kaplan-Meier Estimate
Tyrosine-kinase inhibitor
chemistry.chemical_compound
0302 clinical medicine
Older patients
Renal cell carcinoma
Outcome Assessment
Health Care
Anilides
Fatigue
Hazard ratio
Age Factors
Middle Aged
Vascular endothelial growth factor receptor
Kidney Neoplasms
030220 oncology & carcinogenesis
Hypertension
Female
medicine.drug
Adult
Diarrhea
medicine.medical_specialty
Cabozantinib
medicine.drug_class
Antineoplastic Agents
Article
03 medical and health sciences
Age
Internal medicine
medicine
Humans
In patient
Everolimus
Carcinoma
Renal Cell
Protein Kinase Inhibitors
Aged
Proportional Hazards Models
Retrospective Studies
business.industry
medicine.disease
Confidence interval
Cancérologie
030104 developmental biology
chemistry
business
Zdroj: Donskov, F, Motzer, R J, Voog, E, Hovey, E, Grüllich, C, Nott, L M, Cuff, K, Gil, T, Jensen, N V, Chevreau, C, Negrier, S, Depenbusch, R, Bergmann, L, Cornelio, I, Champsaur, A, Escudier, B, Pal, S, Powles, T & Choueiri, T K 2020, ' Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma ', European Journal of Cancer, vol. 126 . https://doi.org/10.1016/j.ejca.2019.10.032
European journal of cancer, 126
European journal of cancer (Oxford, England : 1990)
Donskov, F, Motzer, R J, Voog, E, Hovey, E, Grüllich, C, Nott, L M, Cuff, K, Gil, T, Jensen, N V, Chevreau, C, Negrier, S, Depenbusch, R, Bergmann, L, Cornelio, I, Champsaur, A, Escudier, B, Pal, S, Powles, T & Choueiri, T K 2020, ' Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma ', European Journal of Cancer, vol. 126, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.10.032
Popis: Background: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC. Methods: Efficacy and safety in METEOR were retrospectively analysed for three age subgroups
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: